Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | LGALS8 | O00214 | 9/20 | 0.41 |
| ▸ | LGALS3 | P17931 | 8/20 | 0.41 |
| ▸ | FLT3 | P36888 | 3/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.40 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL564765 | 0.90 | KMT2A (0.46) | KMT2AXDHLGALS8LGALS3FLT3 | |
| SCHEMBL564651 | 0.86 | KMT2A (0.60) | KMT2AXDHLGALS8LGALS3FLT3 | |
| SCHEMBL563627 | 0.84 | GCK (0.33) | XDH | |
| SCHEMBL1075818 | 0.82 | GCK (0.33) | XDH | |
| SCHEMBL563631 | 0.82 | GCK (0.34) | — | |
| SCHEMBL564842 | 0.82 | KDM4E (0.60) | KMT2AXDHLGALS8LGALS3 | |
| SCHEMBL1075410 | 0.81 | GCK (0.34) | PDGFRBPDGFRA | |
| SCHEMBL564250 | 0.77 | GCK (0.36) | — | |
| SCHEMBL1078187 | 0.76 | GCK (0.34) | — | |
| SCHEMBL564574 | 0.74 | SYK (0.38) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557805-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-15 | — | — | US | disclosed |
| US-20120035163-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-02-09 | — | — | US | disclosed |
| EP-2371826-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035163-A1 | NOVEL FUSED RING COMPOUND AND USE THEREOF | GPR119, GCKR, SLC5A1 | KMT2A 1470/4885XDH 859/4885LGALS8 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.